Sensus Healthcare (SRTS) to Announce Quarterly Earnings on Monday

Sensus Healthcare (NASDAQ:SRTS) is expected to release its Q2 2026 results after the market closes on Monday, August 3rd. Analysts expect Sensus Healthcare to announce earnings of ($0.1250) per share and revenue of $4.6010 million for the quarter. Investors are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:30 PM ET.

Sensus Healthcare (NASDAQ:SRTS) last announced its earnings results on Thursday, May 7th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.04). Sensus Healthcare had a negative return on equity of 15.79% and a negative net margin of 34.50%.The company had revenue of $3.39 million for the quarter, compared to analyst estimates of $5.32 million.

Sensus Healthcare Stock Up 0.7%

Shares of NASDAQ SRTS opened at $2.91 on Friday. Sensus Healthcare has a 12 month low of $2.66 and a 12 month high of $5.92. The company has a market cap of $47.90 million, a price-to-earnings ratio of -6.19 and a beta of 1.09. The business has a fifty day simple moving average of $2.94 and a 200-day simple moving average of $3.79.

Institutional Trading of Sensus Healthcare

Several institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC lifted its position in Sensus Healthcare by 2.5% in the 2nd quarter. Geode Capital Management LLC now owns 153,917 shares of the company’s stock worth $730,000 after buying an additional 3,766 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Sensus Healthcare in the fourth quarter worth $79,000. State Street Corp raised its holdings in shares of Sensus Healthcare by 5.2% during the fourth quarter. State Street Corp now owns 69,252 shares of the company’s stock worth $276,000 after acquiring an additional 3,400 shares in the last quarter. Ingalls & Snyder LLC acquired a new stake in Sensus Healthcare during the fourth quarter valued at $219,000. Finally, Greenline Wealth Management LLC purchased a new position in Sensus Healthcare in the fourth quarter valued at about $513,000. 25.30% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have commented on SRTS. Wall Street Zen lowered shares of Sensus Healthcare from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 9th. Weiss Ratings restated a “sell (d)” rating on shares of Sensus Healthcare in a report on Friday, July 17th. Finally, Citigroup restated a “buy” rating on shares of Sensus Healthcare in a research report on Friday, May 8th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $6.88.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.